Watching CytoSorbents; Hearing Zacks Small-Cap Research Sets $6 Price Target; Says CytoSorbents Reports 2nd Quarter 2023 Financial And Operating Results Which Showed Strong Product Revenue Growth And An Improved Cost Structure
Watching CytoSorbents; Hearing Zacks Small-Cap Research Sets $6 Price Target; Says CytoSorbents Reports 2nd Quarter 2023 Financial And Operating Results Which Showed Strong Product Revenue Growth And An Improved Cost Structure
觀看 CytoSorbents；Hearing Zacks Small-Cap Research 設定了 6 美元的目標股價；CytoSorbents 公佈了 2023 年第二季度的財務和經營業績，顯示產品收入強勁增長，成本結構有所改善
Watching CytoSorbents; Hearing Zacks Small-Cap Research Sets $6 Price Target; Says CytoSorbents Reports 2nd Quarter 2023 Financial And Operating Results Which Showed Strong Product Revenue Growth And An Improved Cost Structure
觀看CytoSorbents；聽到ZacksSmall-Cap Research設定6美元目標價；表示CytoSorbents報告2023年第二季度財務和運營業績顯示產品收入強勁增長和成本結構改善
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。